Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Broadfin Capital Thinks ContraFect Corp (CFRX) Can Prevent 25% of Deaths

Page 1 of 2

According to a recent 13G form filed with the Securities and Exchange Commission, Kevin Kotler‘s Broadfin Capital has initiated a stake in ContraFect Corp (NASDAQ:CFRX) to the tune of 1.42 million shares. The holding represents 7.0% of the $92.87 million biotechnology company’s outstanding common stock. Kevin Kotler launched his healthcare-focused New York-based fund in 2005 with the intention to emphasize company fundamentals and to invest with a long-term horizon. Throughout his career, Kotler has been analyzing and investing in medical technology companies and today Broadfin has investments in all the major sub-sectors of the healthcare industry. The fund currently has more than $1 billion in assets under management, and the market value of its public equity portfolio stood at $1.28 billion at the end of March. Although some holdings are from the finance and materials sectors, healthcare represents 89% of the fund’s portfolio value. Aside from ContraFect Corp (NASDAQ:CFRX), the top micro-cap picks of the fund at the end of March included Flamel Technologies S.A. (ADR) (NASDAQ:FLML) and Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR).

Kevin Kotler

We don’t just track the latest moves of hedge funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research which showed that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests, and easily beating the most popular large-cap picks of funds, which nonetheless get the majority of their collective capital. Why pay fees to invest in both the best and worst ideas of a particular hedge fund when you can simply mimic only the very best ideas of the best fund managers on your own? Since the beginning of forward testing in August 2012, the Insider Monkey small-cap strategy has outperformed the market every year, returning 142%, nearly 2.5 times greater returns than the S&P 500 during the same period (see more details).

Kevin Kotler
Kevin Kotler
Broadfin Capital

Hospital acquired infections are currently the fourth-leading cause of death in U.S. after heart disease, cancer, and stroke. ContraFect Corp (NASDAQ:CFRX) is focused on the development of therapeutic protein and antibody products for such life-threatening, drug-resistant infectious diseases. The company held its IPO in September last year and is down by about 9% since then, however, the stock has appreciated by nearly 36% year-to-date.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!